Daliresp: A Targeted Approach to COPD Management

Daliresp

Price from 58.48 $

Show more

Product dosage: 500 mg
Package (num)	Per tab	Price	Buy
30	$1.95	$58.48 (0%)	🛒 Add to cart
60	$1.58	$116.96 $94.60 (19%)	🛒 Add to cart
90	$1.36	$175.44 $122.12 (30%)	🛒 Add to cart
120	$1.18	$233.92 $141.90 (39%)	🛒 Add to cart
180	$1.05 Best per tab	$350.88 $189.20 (46%)	🛒 Add to cart

Daliresp (roflumilast) is a selective phosphodiesterase 4 (PDE4) inhibitor indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It represents a distinct class of maintenance treatment, functioning as an oral anti-inflammatory agent that targets the underlying pathophysiology of the disease. Unlike bronchodilators, which primarily address symptoms of bronchoconstriction, Daliresp works systemically to decrease the frequency of flare-ups, or exacerbations, that are a major driver of disease progression, morbidity, and healthcare utilization. This profile provides a comprehensive expert overview of its clinical application, mechanism, and appropriate use.

Features

• Active Ingredient: Roflumilast
• Pharmacologic Class: Selective Phosphodiesterase 4 (PDE4) Inhibitor
• Dosage Form: Film-coated, unscored tablet
• Available Strength: 500 mcg
• Administration: Oral, once daily
• Mechanism of Action: Inhibition of PDE4 enzyme, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. This action results in broad anti-inflammatory effects within the lung parenchyma and airways.

Benefits

• Reduces Exacerbation Risk: Clinically proven to significantly decrease the rate of moderate-to-severe COPD exacerbations in a high-risk patient population.
• Targets Underlying Inflammation: Addresses the chronic inflammatory component of COPD, a key driver of disease progression and lung function decline.
• Oral Dosing Convenience: Offers a once-daily oral regimen, which may improve adherence compared to complex inhaled therapeutic regimens.
• Complementary Mechanism: Provides additive benefits when used alongside long-acting bronchodilators (LABA/LAMA), acting on a different pathway of the disease.
• Potential to Preserve Lung Function: By reducing inflammatory insults from exacerbations, long-term use may help slow the accelerated decline in FEV1.

Common use

Daliresp is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It is not a bronchodilator and is not indicated for the relief of acute bronchospasm. Its use is typically reserved for patients whose disease is not adequately controlled by other maintenance therapies, such as long-acting muscarinic antagonists (LAMA) and long-acting beta2-agonists (LABA). It is considered a add-on therapy to these standard bronchodilator regimens, not a replacement.

Dosage and direction

The recommended dosage of Daliresp is one 500 mcg tablet taken orally once daily, with or without food.

• Dose Titration: To improve gastrointestinal tolerability, a dose titration schedule is recommended. Treatment should be initiated with one 250 mcg tablet once daily for 4 weeks, followed by an increase to the maintenance dose of one 500 mcg tablet once daily. The 250 mcg tablet is supplied for this titration purpose only.
• Administration: The tablet should be swallowed whole; it should not be crushed, split, or chewed.
• Timing: It can be taken at any time of day, but taking it at the same time each day is advised to maintain consistent drug levels and support patient adherence.

Precautions

• Psychiatric Events: Daliresp has been associated with an increased risk of psychiatric events such as insomnia, anxiety, depression, and, rarely, suicidal ideation. Patients, their caregivers, and families should be advised to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other behavioral changes. If such changes occur, discontinuation of Daliresp must be considered.
• Weight Decrease: Patients treated with Daliresp experienced a mean weight loss of approximately 2 kg over a 12-month period. The weight loss appears to occur primarily in the first few months and then stabilizes. Patients should have their body weight monitored regularly. Unexplained or clinically significant weight loss may necessitate discontinuation of therapy.
• Nausea and Diarrhea: These are the most common adverse reactions. These symptoms are often transient and may be managed by the initial dose titration. Persistent symptoms may require medical evaluation.
• Drug Interactions: Caution is advised when co-administering with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) or inhibitors (e.g., cimetidine, erythromycin, ketoconazole, fluvoxamine, enoxacin), as they may alter the plasma concentration and efficacy of roflumilast.

Contraindications

Daliresp is contraindicated in patients with:

• Moderate to severe liver impairment (Child-Pugh B or C).
• A known hypersensitivity to roflumilast or any excipient in the product.

Possible side effect

The most common adverse reactions (occurring in ≥2% of patients and more frequently than placebo) are:

• Diarrhea
• Weight decreased
• Nausea
• Headache
• Insomnia
• Back pain
• Decreased appetite
• Dizziness
• Influenza
• Vomiting
• Tremor
• Dyspepsia
• Fatigue
• Abdominal pain
• Muscle spasms
• Rhinitis Less common but serious side effects include psychiatric events (e.g., depression, suicidal ideation) and persistent, unexplained weight loss.

Drug interaction

Roflumilast is primarily metabolized by CYP3A4 and CYP1A2 enzymes. Concomitant use with other drugs that affect these pathways can alter its plasma concentration.

• CYP3A4 Inducers: Drugs like rifampicin, phenobarbital, carbamazepine, and phenytoin may significantly decrease the systemic exposure to roflumilast, potentially reducing its therapeutic effect. Concomitant use is not recommended.
• CYP3A4 Inhibitors and Dual Inhibitors: Drugs like ketoconazole (and other strong CYP3A4 inhibitors), fluvoxamine (a CYP1A2/CYP2C19 inhibitor), and enoxacin (a CYP1A2 inhibitor) may increase roflumilast exposure, potentially increasing the risk of adverse effects. The benefit-risk balance should be carefully considered.

Missed dose

If a dose is missed, it should be taken as soon as it is remembered on the same day. If a patient remembers a missed dose on the day they are scheduled to take the next dose, the missed dose should be skipped. The patient should not take a double dose to make up for the missed dose. Patients should be instructed to maintain their regular once-daily schedule.

Overdose

There is limited clinical experience with overdose. Based on the drug’s pharmacology, signs and symptoms of overdose may include severe nausea, vomiting, diarrhea, headache, dizziness, lightheadedness, and possibly cardiac palpitations. There is no specific antidote for roflumilast overdose. Treatment should consist of general supportive measures, including monitoring of vital signs and observation of the clinical status of the patient.

Storage

• Store Daliresp tablets at room temperature, between 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
• Keep the bottle tightly closed to protect from moisture and light.
• Keep out of the reach of children and pets.

Disclaimer

This information is intended for educational and informational purposes only for healthcare professionals and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. The content is derived from the manufacturer’s prescribing information but may not be exhaustive. Always refer to the full official prescribing information before initiating or modifying any treatment regimen. Healthcare providers should exercise their own professional judgment in determining the appropriate course of patient care, considering the individual patient’s condition, contraindications, and potential adverse effects.

Reviews

• Clinical Perspective (Pulmonologist): “In my practice, Daliresp has been a valuable tool for a specific subset of patients—those with frequent exacerbations despite optimal bronchodilator therapy. It’s not a first-line agent, but its unique anti-inflammatory mechanism offers a different approach. The side effect profile, particularly GI issues and weight loss, requires careful patient selection, education, and monitoring. When tolerated, it can meaningfully reduce exacerbation frequency and improve a patient’s quality of life.”
• Patient Experience (Anonymous, 5-year user): “The first month was rough with nausea, but my doctor started me on the lower dose as recommended. After that, the side effects faded. I haven’t had to go on prednisone for a flare-up in over two years now, which is a huge win for me. I do weigh myself every week as advised, and my weight has been stable after the initial drop. It’s one more pill, but it’s been worth it for the stability.”
• Systematic Review Analysis: “Meta-analyses of randomized controlled trials consistently demonstrate that roflumilast significantly reduces the rate of moderate and severe exacerbations in patients with severe COPD, chronic bronchitis, and a history of exacerbations. The number needed to treat (NNT) to prevent one exacerbation is favorable, though this must be balanced against the number needed to harm (NNH) for common adverse effects like diarrhea. Its role is firmly established in international treatment guidelines (e.g., GOLD report) as an add-on therapy for high-risk patients.”